

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/38544> holds various files of this Leiden University dissertation

Author: Calkoen, Friso

Title: Mesenchymal stromal cells in pediatric disease : pathophysiology and treatment

Issue Date: 2016-03-16

The background of the page is a dense, abstract pattern of organic, cell-like shapes in various colors: yellow, green, blue, red, and grey. Each shape contains a smaller, semi-transparent circle of the same color. Two horizontal black lines are drawn across the page, one above the title and one below the word 'References'.

Chapter 8.

References

Reference List

A

- Aalbers, A.M., van den Heuvel-Eibrink MM, Baumann, I. *et al.* T-cell receptor Vbeta skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. *Blood Cancer J.* 2014;4:e209.
- Aanei, C.M., Eloae, F.Z., Flandrin-Gresta, P. *et al.* Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. *Exp. Cell Res.* 2011;317(18):2616-2629.
- Aanei, C.M., Flandrin, P., Eloae, F.Z. *et al.* Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. *Stem Cells Dev.* 2012;21(10):1604-1615.
- Abdelrazik, H., Spaggiari, G.M., Chiossone, L. *et al.* Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. *Eur. J. Immunol.* 2011;41(11):3281-3290.
- Aggarwal, S. and Pittenger, M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005;105(4):1815-1822.
- Aizawa, S., Nakano, M., Iwase, O. *et al.* Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. *Leuk. Res.* 1999;23(3):239-246.
- Akira, S., Uematsu, S., and Takeuchi, O. Pathogen recognition and innate immunity. *Cell* 2006;124(4):783-801.
- Almeida-Porada, G., Porada, C.D., Tran, N. *et al.* Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. *Blood* 2000;95(11):3620-3627.
- Alvi, S., Shaher, A., Shetty, V. *et al.* Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. *Leuk. Res.* 2001;25(11):941-954.
- Amaral, A.T., Manara, M.C., Berghuis, D. *et al.* Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications. *PLoS. One.* 2014;9(2):e85814.
- Aoyagi, M., Furusawa, S., Waga, K. *et al.* Suppression of normal hematopoiesis in acute leukemia: effect of leukemic cells on bone marrow stromal cells and hematopoietic progenitor cells. *Intern. Med.* 1994;33(5):288-295.
- Ara, T. and Declerck, Y.A. Interleukin-6 in bone metastasis and cancer progression. *Eur. J. Cancer* 2010;46(7):1223-1231.
- Arranz, L., Sanchez-Aguilera, A., Martin-Perez, D. *et al.* Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. *Nature* 2014;512(7512):78-81.
- Aubert, G., Hassan-Walker, A.F., Madrigal, J.A. *et al.* Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. *J. Infect. Dis.* 2001;184(8):955-963.
- Augello, A., Tasso, R., Negrini, S.M. *et al.* Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. *Arthritis Rheum.* 2007;56(4):1175-1186.
- Ayabe, T., Satchell, D.P., Wilson, C.L. *et al.* Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. *Nat. Immunol.* 2000;1(2):113-118.
- Ayala, F., Dewar, R., Kieran, M. *et al.* Contribution of bone microenvironment to leukemogenesis and leukemia progression. *Leukemia* 2009;23(12):2233-2241.

B

- Bach, F.H., Albertini, R.J., Joo, P. *et al.* Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. *Lancet* 1968;2(7583):1364-1366.
- Bacigalupo, A., Valle, M., Podesta, M. *et al.* T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. *Exp. Hematol.* 2005;33(7):819-827.
- Baird, K., Cooke, K., and Schultz, K.R. Chronic graft-versus-host disease (GVHD) in children. *Pediatr. Clin. North Am.* 2010;57(1):297-322.
- Baldwin, A., Kingman, H., Darville, M. *et al.* Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. *Bone Marrow Transplant.* 2000;26(12):1333-1338.
- Ball, L., Bredius, R., Lankester, A. *et al.* Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. *Leukemia* 2008a;22(6):1256-1257.
- Ball, L., Bredius, R., Lankester, A. *et al.* Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. *Leukemia* 2008b;22(6):1256-1257.
- Ball, L.M., Bernardo, M.E., Roelofs, H. *et al.* Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. *Blood* 2007;110(7):2764-2767.
- Ball, L.M., Bernardo, M.E., Roelofs, H. *et al.* Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. *Br. J. Haematol.* 2013;2013;163(4):501-509.
- Ball, L.M. and Egeler, R.M. Acute GvHD: pathogenesis and classification. *Bone Marrow Transplant.* 2008c;41 Suppl 2:S58-S64.
- Bandzar, S., Gupta, S., and Platt, M.O. Crohn's disease: a review of treatment options and current research. *Cell Immunol.* 2013;286(1-2):45-52.
- Barker, J.E. Early transplantation to a normal microenvironment prevents the development of Steel hematopoietic stem cell defects. *Exp. Hematol.* 1997;25(6):542-547.
- Bartholomew, A., Sturgeon, C., Siatskas, M. *et al.* Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. *Exp. Hematol.* 2002;30(1):42-48.
- Ben, A.N., Jenhani, F., Regaya, Z. *et al.* Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. *Stem Cell Res. Ther.* 2012;3(1):6.
- Bernardo, M.E., Avanzini, M.A., Ciccocioppo, R. *et al.* Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. *Cytotherapy.* 2009;11(7):825-836.
- Bernardo, M.E., Avanzini, M.A., Perotti, C. *et al.* Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. *J. Cell Physiol* 2007a;211(1):121-130.
- Bernardo, M.E., Ball, L.M., Cometa, A.M. *et al.* Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. *Bone Marrow Transplant.* 2011;46(2):200-207.
- Bernardo, M.E., Emons, J.A., Karperien, M. *et al.* Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. *Connect. Tissue Res.* 2007b;48(3):132-140.
- Bernardo, M.E., Zaffaroni, N., Novara, F. *et al.* Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit

- telomere maintenance mechanisms. *Cancer Res.* 2007c;**67**(19):9142-9149.
- Beukelman,T., Patkar,N.M., Saag,K.G. *et al.* 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res. (Hoboken.)* 2011;**63**(4):465-482.
- Beyth,S., Borovsky,Z., Mevorach,D. *et al.* Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood* 2005;**105**(5):2214-2219.
- Bianco,P., Cao,X., Frenette,P.S. *et al.* The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. *Nat. Med.* 2013;**19**(1):35-42.
- Blau,O., Baldus,C.D., Hofmann,W.K. *et al.* Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. *Blood* 2011;**118**(20):5583-5592.
- Blau,O., Hofmann,W.K., Baldus,C.D. *et al.* Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. *Exp. Hematol.* 2007;**35**(2):221-229.
- Bocelli-Tyndall,C., Bracci,L., Schaeren,S. *et al.* Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15. *Ann. Rheum. Dis.* 2009;**68**(8):1352-1359.
- Bocelli-Tyndall,C., Bracci,L., Spagnoli,G. *et al.* Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. *Rheumatology. (Oxford)* 2007;**46**(3):403-408.
- Boeckh,M., Leisenring,W., Riddell,S.R. *et al.* Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. *Blood* 2003;**101**(2):407-414.
- Borojevic,R., Roela,R.A., Rodarte,R.S. *et al.* Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. *Leuk. Res.* 2004;**28**(8):831-844.
- Brinkman,D.M., de Kleer,I.M., ten Cate R. *et al.* Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. *Arthritis Rheum.* 2007;**56**(7):2410-2421.
- Broers,A.E., van Der Holt,R., van Esser,J.W. *et al.* Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. *Blood* 2000;**95**(7):2240-2245.
- Bronkhorst,I.H., Maat,W., Jordanova,E.S. *et al.* Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. *Arch. Pathol. Lab Med.* 2011;**135**(8):1042-1047.
- Buddingh,E.P., Ruslan,S.E., Reijnders,C.M. *et al.* Mesenchymal stromal cells of osteosarcoma patients do not show evidence of neoplastic changes during long-term culture. *Clin. Sarcoma. Res.* 2015;**5**:16.
- Bueger de,M., Bakker,A., Bontkes,H. *et al.* High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. *Bone Marrow Transplant.* 1993;**11**(5):363-368.
- Buron,F., Perrin,H., Malcus,C. *et al.* Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. *Transplant. Proc.* 2009;**41**(8):3347-3352.
- Busca,A., Locatelli,F., Marmont,F. *et al.* Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. *Am. J. Hematol.* 2007;**82**(1):45-52.

Butler,J.M., Nolan,D.J., Vertes,E.L. *et al.* Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. *Cell Stem Cell* 2010;**6**(3):251-264.

C

Calkoen,F.G., Brinkman,D.M., Vervat,C. *et al.* Mesenchymal stromal cells isolated from children with systemic juvenile idiopathic arthritis suppress innate and adaptive immune responses. *Cytotherapy*. 2013a;**15**(3):280-291.

Calkoen,F.G., Jol-van der Zijde CM, Mearin,M.L. *et al.* Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment and biomarkers for prediction of the response. *Biol. Blood Marrow Transplant*. 2013b;**19**(11):1590-1599.

Calkoen,F.G., Vervat,C., van Pel,M. *et al.* Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro. *Stem Cell Res*. 2015;**14**(2):198-210.

Calloni,R., Cordero,E.A., Henriques,J.A. *et al.* Reviewing and updating the major molecular markers for stem cells. *Stem Cells Dev*. 2013;**22**(9):1455-1476.

Cantoni,N., Hirsch,H.H., Khanna,N. *et al.* Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. *Biol. Blood Marrow Transplant*. 2010;**16**(9):1309-1314.

Casado-Díaz,A., Santiago-Mora,R., Jimenez,R. *et al.* Cryopreserved human bone marrow mononuclear cells as a source of mesenchymal stromal cells: application in osteoporosis research. *Cytotherapy*. 2008;**10**(5):460-468.

Chakrabarti,S., Mautner,V., Osman,H. *et al.* Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. *Blood* 2002;**100**(5):1619-1627.

Che,N., Li,X., Zhang,L. *et al.* Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression. *J. Immunol.* 2014;**193**(10):5306-5314.

Che,N., Li,X., Zhou,S. *et al.* Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. *Cell Immunol.* 2012;**274**(1-2):46-53.

Cheshier,S.H., Morrison,S.J., Liao,X. *et al.* In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc. Natl. Acad. Sci. U. S. A* 1999;**96**(6):3120-3125.

Chiesa,S., Morbelli,S., Morando,S. *et al.* Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. *Proc. Natl. Acad. Sci. U. S. A* 2011;**108**(42):17384-17389.

Chillemi,A., Zaccarello,G., Quarona,V. *et al.* Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. *Mol. Med.* 2013;**19**:99-108.

Chitteti,B.R., Cheng,Y.H., Kacena,M.A. *et al.* Hierarchical organization of osteoblasts reveals the significant role of CD166 in hematopoietic stem cell maintenance and function. *Bone* 2013;**54**(1):58-67.

Ciccocioppo,R., Bernardo,M.E., Sgarella,A. *et al.* Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. *Gut* 2011;**60**(6):788-798.

Claus,R., Hackanson,B., Poetsch,A.R. *et al.* Quantitative analyses of DAPK1 methylation in AML and MDS. *Int. J. Cancer* 2012;**131**(2):E138-E142.

Cohnheim,J. Ueber Entzündung und Eiterung. *Arch. Path. Anat. Physiol. Klin. Med.* 1867;**40**:1-79.

Conforti,A., Biagini,S., Del,B.F. *et al.* Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia. *PLoS. One.* 2013;**8**(11):e76989.

- Corcione,A., Benvenuto,F., Ferretti,E. *et al.* Human mesenchymal stem cells modulate B-cell functions. *Blood* 2006;**107**(1):367-372.
- Corre,J., Mahtouk,K., Attal,M. *et al.* Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. *Leukemia* 2007;**21**(5):1079-1088.
- Couriel,D., Caldera,H., Champlin,R. *et al.* Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. *Cancer* 2004a;**101**(9):1936-1946.
- Couriel,D., Saliba,R., Hicks,K. *et al.* Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood* 2004b;**104**(3):649-654.
- Courties,G., Herisson,F., Sager,H.B. *et al.* Ischemic stroke activates hematopoietic bone marrow stem cells. *Circ. Res.* 2015;**116**(3):407-417.
- Coutinho,L.H., Geary,C.G., Chang,J. *et al.* Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). *Br. J. Haematol.* 1990;**75**(1):16-25.
- Crop,M.J., Korevaar,S.S., de,K.R. *et al.* Human mesenchymal stem cells are susceptible to lysis by CD8+ T-cells and NK cells. *Cell Transplant.* 2011.
- Csaszar,E., Wang,W., Usenko,T. *et al.* Blood stem cell fate regulation by Delta-1 mediated rewiring of IL-6 paracrine signaling. *Blood* 2013.
- Cwynarski,K., Ainsworth,J., Cobbold,M. *et al.* Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. *Blood* 2001;**97**(5):1232-1240.
- cells regulate human stem cell migration and development in NOD/SCID chimeric mice. *Exp. Hematol.* 2006;**34**(8):967-975.
- Davies,S.M., Wang,D., Wang,T. *et al.* Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. *Biol. Blood Marrow Transplant.* 2009;**15**(3):360-366.
- Dayer,J.M. and Choy,E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. *Rheumatology. (Oxford)* 2010;**49**(1):15-24.
- Dazzi,F. and Krampera,M. Mesenchymal stem cells and autoimmune diseases. *Best. Pract. Res. Clin. Haematol.* 2011;**24**(1):49-57.
- De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. *Curr. Opin. Rheumatol.* 2009;**21**(5):533-537.
- de la Portilla,F., Alba,F., Garcia-Olmo,D. *et al.* Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. *Int. J. Colorectal Dis.* 2013;**28**(3):313-323.
- de Vries,A.C., Zwaan,C.M., and van den Heuvel-Eibrink MM. Molecular basis of juvenile myelomonocytic leukemia. *Haematologica* 2010;**95**(2):179-182.
- Deeg,H.J. How I treat refractory acute GVHD. *Blood* 2007;**109**(10):4119-4126.
- Diak,P., Siegel,J., La Grenade L. *et al.* Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. *Arthritis Rheum.* 2010;**62**(8):2517-2524.
- Dickinson,A.M. Non-HLA genetics and predicting outcome in HSCT. *Int. J. Immunogenet.* 2008;**35**(4-5):375-380.
- Ding,L., Saunders,T.L., Enikolopov,G. *et al.* Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature* 2012;**481**(7382):457-462.
- Djouad,F., Fritz,V., Apparailly,F. *et al.* Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor

D

- Dander,E., Lucchini,G., Vinci,P. *et al.* Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. *Leukemia* 2012;**26**(7):1681-1684.
- Dar,A., Kollet,O., and Lapidot,T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal

- alpha in collagen-induced arthritis. *Arthritis Rheum.* 2005;**52**(5):1595-1603.
- Dominici,M., Le Blanc,K., Mueller,I. *et al.* Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy.* 2006;**8**(4):315-317.
- Duijvestein,M., Vos,A.C., Roelofs,H. *et al.* Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. *Gut* 2010;**59**(12):1662-1669.
- ## E
- Echavarria,M., Forman,M., van Tol,M.J. *et al.* Prediction of severe disseminated adenovirus infection by serum PCR. *Lancet* 2001;**358**(9279):384-385.
- Ertault-Daneshpouy,M., Leboeuf,C., Lemann,M. *et al.* Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. *Blood* 2004;**103**(12):4681-4684.
- ## F
- Fang,B., Song,Y., Zhao,R.C. *et al.* Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. *Transplant. Proc.* 2007;**39**(5):1710-1713.
- Farge,D., Labopin,M., Tyndall,A. *et al.* Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. *Haematologica* 2010;**95**(2):284-292.
- Fenaux,P., Mufti,G.J., Hellstrom-Lindberg,E. *et al.* Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol.* 2009;**10**(3):223-232.
- Ferrara,J.L., Harris,A.C., Greenson,J.K. *et al.* Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. *Blood* 2011;**118**(25):6702-6708.
- Ferrara,J.L., Levine,J.E., Reddy,P. *et al.* Graft-versus-host disease. *Lancet* 2009;**373**(9674):1550-1561.
- Ferrer,R.A., Wobus,M., List,C. *et al.* Mesenchymal stromal cells from patients with myelodysplastic syndromedisplay distinct functional alterations that are modulated by lenalidomide. *Haematologica* 2013;**98**(11):1677-1685.
- Flomenberg,P., Babbitt,J., Drobyski,W.R. *et al.* Increasing incidence of adenovirus disease in bone marrow transplant recipients. *J. Infect. Dis.* 1994;**169**(4):775-781.
- Flores-Figueroa,E., Arana-Trejo,R.M., Gutierrez-Espindola,G. *et al.* Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. *Leuk. Res.* 2005;**29**(2):215-224.
- Flores-Figueroa,E., Gutierrez-Espindola,G., Montesinos,J.J. *et al.* In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. *Leuk. Res.* 2002;**26**(7):677-686.
- Flores-Figueroa,E., Montesinos,J.J., Flores-Guzman,P. *et al.* Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. *Leuk. Res.* 2008;**32**(9):1407-1416.
- Flores-Figueroa,E., Varma,S., Montgomery,K. *et al.* Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. *Lab Invest* 2012;**92**(9):1330-1341.
- Franceschini,A., Szklarczyk,D., Frankild,S. *et al.* STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res.* 2013;**41**(Database issue):D808-D815.
- Friedenstein,A.J., Petrakova,K.V., Kurolesova,A.I. *et al.* Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation* 1968;**6**(2):230-247.

Fujii,H., Luo,Z.J., Kim,H.J. *et al.* Humanized Chronic Graft-versus-Host Disease in NOD-SCID $\text{il2rgamma}^{-/-}$ (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation. *PLoS. One.* 2015;**10**(7):e0133216.

G

Garcia-Olmo,D., Garcia-Arranz,M., Herreros,D. *et al.* A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. *Dis. Colon Rectum* 2005;**48**(7):1416-1423.

Gatti,R.A., Meuwissen,H.J., Allen,H.D. *et al.* Immunological reconstitution of sex-linked lymphopenic immunological deficiency. *Lancet* 1968;**2**(7583):1366-1369.

Ghannam,S., Pene,J., Moquet-Torcy,G. *et al.* Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. *J. Immunol.* 2010;**185**(1):302-312.

Gharibi,T., Ahmadi,M., Seyfizadeh,N. *et al.* Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. *Cell Immunol.* 2015;**293**(2):113-121.

Gieseke,F., Bohringer,J., Bussolari,R. *et al.* Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. *Blood* 2010;**116**(19):3770-3779.

Glaubach,T., Robinson,L.J., and Corey,S.J. Pediatric myelodysplastic syndromes: they do exist! *J. Pediatr. Hematol. Oncol.* 2014;**36**(1):1-7.

Gohring,G., Michalova,K., Beverloo,H.B. *et al.* Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. *Blood* 2010;**116**(19):3766-3769.

Goker,H., Haznedaroglu,I.C., and Chao,N.J. Acute graft-vs-host disease: pathobiology and management. *Exp. Hematol.* 2001;**29**(3):259-277.

Gonzalez,M.A., Gonzalez-Rey,E., Rico,L. *et al.* Adipose-derived mesenchymal stem cells

alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. *Gastroenterology* 2009;**136**(3):978-989.

Greenbaum,A., Hsu,Y.M., Day,R.B. *et al.* CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature* 2013;**495**(7440):227-230.

Griffiths,S., Baraniak,P.R., Copland,I.B. *et al.* Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation in vitro. *Cytotherapy.* 2013;**15**(12):1469-1483.

Groen,R.W., Noort,W.A., Raymakers,R.A. *et al.* Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. *Blood* 2012;**120**(3):e9-e16.

Groh,M.E., Maitra,B., Szekely,E. *et al.* Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. *Exp. Hematol.* 2005;**33**(8):928-934.

Gunn,W.G., Conley,A., Deininger,L. *et al.* A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. *Stem Cells* 2006;**24**(4):986-991.

H

Haack-Sorensen,M., Bindsvlev,L., Mortensen,S. *et al.* The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. *Cytotherapy.* 2007;**9**(4):328-337.

Hammond-Martel,I., Yu,H., and Affar,e.B. Roles of ubiquitin signaling in transcription regulation. *Cell Signal.* 2012;**24**(2):410-421.

Han,Q., Sun,Z., Liu,L. *et al.* Impairment in immunomodulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients. *Leuk. Res.* 2007;**31**(11):1469-1478.

- Handgretinger,R., Kurtzberg,J., and Egeler,R.M. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. *Pediatr. Clin. North Am.* 2008;**55**(1):71-96.
- Harris,A.C., Ferrara,J.L., Braun,T.M. *et al.* Plasma biomarkers of lower gastrointestinal and liver acute GVHD. *Blood* 2012;**119**(12):2960-2963.
- Hasle,H., Baumann,I., Bergstrasser,E. *et al.* The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). *Leukemia* 2004;**18**(12):2008-2014.
- Hasle,H. and Niemeyer,C.M. Advances in the prognostication and management of advanced MDS in children. *Br. J. Haematol.* 2011;**154**(2):185-195.
- Hasle,H., Niemeyer,C.M., Chessells,J.M. *et al.* A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. *Leukemia* 2003;**17**(2):277-282.
- Heath,D.J., Chantry,A.D., Buckle,C.H. *et al.* Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. *J. Bone Miner. Res.* 2009;**24**(3):425-436.
- Hemeda,H., Giebel,B., and Wagner,W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. *Cytotherapy.* 2014;**16**(2):170-180.
- Herrmann,R., Sturm,M., Shaw,K. *et al.* Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. *Int. J. Hematol.* 2012;**95**(2):182-188.
- Hirabayashi,S., Flotho,C., Moetter,J. *et al.* Spli-ceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. *Blood* 2012;**119**(11):e96-e99.
- Hirayama,Y., Kohgo,Y., Matsunaga,T. *et al.* Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anaemia and myelodysplastic syndrome. *Br. J. Haematol.* 1993;**85**(4):676-683.
- Hochberg,Y. and Benjamini,Y. More powerful procedures for multiple significance testing. *Stat. Med.* 1990;**9**(7):811-818.
- Hoda,D., Pidala,J., Salgado-Vila,N. *et al.* Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. *Bone Marrow Transplant.* 2010;**45**(8):1347-1351.
- Hoen 't,P.A., Ariyurek,Y., Thygesen,H.H. *et al.* Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. *Nucleic Acids Res.* 2008;**36**(21):e141.
- Holtan,S.G., Pasquini,M., and Weisdorf,D.J. Acute graft-versus-host disease: a bench-to-bedside update. *Blood* 2014;**124**(3):363-373.
- Horneff,G., Foeldvari,I., Minden,K. *et al.* Report on malignancies in the German juvenile idiopathic arthritis registry. *Rheumatology. (Oxford)* 2011;**50**(1):230-236.
- Horowitz,M.M., Gale,R.P., Sondel,P.M. *et al.* Graft-versus-leukemia reactions after bone marrow transplantation. *Blood* 1990;**75**(3):555-562.
- Horwitz,E.M., Le,B.K., Dominici,M. *et al.* Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy.* 2005;**7**(5):393-395.
- Howard,D.S., Phillips II,G.L., Reece,D.E. *et al.* Adenovirus infections in hematopoietic stem cell transplant recipients. *Clin. Infect. Dis.* 1999;**29**(6):1494-1501.
- J**
- Jitschin,R., Mougiakakos,D., von,B.L. *et al.* Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. *Stem Cells* 2013;**31**(8):1715-1725.
- Jones,E., Churchman,S.M., English,A. *et al.* Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. *Ann. Rheum. Dis.* 2010;**69**(2):450-457.

K

- Kang,H.S., Habib,M., Chan,J. *et al.* A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. *Exp. Hematol.* 2005;**33**(7):796-803.
- Karlic,H., Herrmann,H., Varga,F. *et al.* The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. *Crit Rev. Oncol. Hematol.* 2013.
- Karlsson,H., Samarasinghe,S., Ball,L.M. *et al.* Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. *Blood* 2008;**112**(3):532-541.
- Karussis,D., Karageorgiou,C., Vaknin-Dembinsky,A. *et al.* Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. *Arch. Neurol.* 2010;**67**(10):1187-1194.
- Kass,D.J., Yu,G., Loh,K.S. *et al.* Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury. *Am. J. Pathol.* 2012;**180**(5):1963-1978.
- Kebrlraei,P., Isola,L., Bahceci,E. *et al.* Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. *Biol. Blood Marrow Transplant.* 2009;**15**(7):804-811.
- Kerbaui,D.M., Lesnikov,V., Torok-Storb,B. *et al.* Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. *Blood* 2004;**104**(7):2202-2203.
- Klaus,M., Stavroulaki,E., Kastrinaki,M.C. *et al.* Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. *Stem Cells Dev.* 2010;**19**(7):1043-1054.
- Koc,O.N., Gerson,S.L., Cooper,B.W. *et al.* Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. *J. Clin. Oncol.* 2000;**18**(2):307-316.
- Kode,A., Manavalan,J.S., Mosialou,I. *et al.* Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. *Nature* 2014;**506**(7487):240-244.
- Kojaoghlanian,T., Flomenberg,P., and Horwitz,M.S. The impact of adenovirus infection on the immunocompromised host. *Rev. Med. Virol.* 2003;**13**(3):155-171.
- Krampera,M., Glennie,S., Dyson,J. *et al.* Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood* 2003;**101**(9):3722-3729.
- Kunisaki,Y., Bruns,I., Scheiermann,C. *et al.* Arteriole niches maintain haematopoietic stem cell quiescence. *Nature* 2013;**502**(7473):637-643.
- Kurtova,A.V., Balakrishnan,K., Chen,R. *et al.* Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. *Blood* 2009;**114**(20):4441-4450.
- Kwon,J.H. and Farrell,R.J. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. *Crit Rev. Oncol. Hematol.* 2005;**56**(1):169-178.

L

- Landfried,K., Zhu,W., Waldhier,M.C. *et al.* Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. *Blood* 2011;**118**(26):6971-6974.
- Lankester,A.C., Bierings,M.B., van Wering,E.R. *et al.* Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual

- disease level before stem cell transplantation. *Leukemia* 2010;**24**(8):1462-1469.
- Larghero,J., Farge,D., Braccini,A. *et al.* Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. *Ann. Rheum. Dis.* 2008;**67**(4):443-449.
- Lazarus,H.M., Koc,O.N., Devine,S.M. *et al.* Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. *Biol. Blood Marrow Transplant.* 2005;**11**(5):389-398.
- Le Blanc,K., Frassoni,F., Ball,L. *et al.* Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet* 2008;**371**(9624):1579-1586.
- Le Blanc,K., Rasmusson,I., Sundberg,B. *et al.* Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* 2004;**363**(9419):1439-1441.
- Le,B.K. and Mougiakakos,D. Multipotent mesenchymal stromal cells and the innate immune system. *Nat. Rev. Immunol.* 2012;**12**(5):383-396.
- Leen,A.M. and Rooney,C.M. Adenovirus as an emerging pathogen in immunocompromised patients. *Br. J. Haematol.* 2005;**128**(2):135-144.
- Lequerre,T., Quartier,P., Rosellini,D. *et al.* Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. *Ann. Rheum. Dis.* 2008;**67**(3):302-308.
- Levine,J.E., Logan,B.R., Wu,J. *et al.* Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. *Blood* 2012;**119**(16):3854-3860.
- Li,Y., Shi,Y., McCaw,L. *et al.* Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. *Blood* 2015;**126**(6):766-778.
- Liang,J., Zhang,H., Hua,B. *et al.* Allogeneic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. *Ann. Rheum. Dis.* 2010;**69**(8):1423-1429.
- Lo,C.C., Fleming,H.E., Wu,J.W. *et al.* Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. *Nature* 2009;**457**(7225):92-96.
- Locatelli,F. and Niemeyer,C.M. How I treat juvenile myelomonocytic leukemia (JMML). *Blood* 2015;**125**(7):1083-1090.
- Locatelli,F., Nollke,P., Zecca,M. *et al.* Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. *Blood* 2005;**105**(1):410-419.
- Loh,M.L. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. *Br. J. Haematol.* 2011;**152**(6):677-687.
- Looyenga,B.D., Resau,J., and MacKeigan,J.P. Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. *PLoS. One.* 2013;**8**(6):e66548.
- Lopez-Villar,O., Garcia,J.L., Sanchez-Guijo,F.M. *et al.* Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. *Leukemia* 2009;**23**(4):664-672.
- Lubkova,O.N., Tzvetaeva,N.V., Momotyuk,K.S. *et al.* VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes. *Bull. Exp. Biol. Med.* 2011;**151**(1):13-15.
- Lucchini,G., Dander,E., Pavan,F. *et al.* Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. *Stem Cells Int.* 2012;**2012**:690236.
- Lucchini,G., Introna,M., Dander,E. *et al.* Platelet-lysate-expanded mesenchymal stromal cells

- as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. *Biol. Blood Marrow Transplant.* 2010;**16**(9):1293-1301.
- Luft, T., Conzelmann, M., Benner, A. *et al.* Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. *Blood* 2007;**110**(13):4535-4542.
- Luft, T., Dietrich, S., Falk, C. *et al.* Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. *Blood* 2011;**118**(6):1685-1692.
- ## M
- MacMillan, M.L., Blazar, B.R., DeFor, T.E. *et al.* Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. *Bone Marrow Transplant.* 2009;**43**(6):447-454.
- MacMillan, M.L., DeFor, T.E., and Weisdorf, D.J. The best endpoint for acute GVHD treatment trials. *Blood* 2010;**115**(26):5412-5417.
- MacMillan, M.L., Weisdorf, D.J., Wagner, J.E. *et al.* Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. *Biol. Blood Marrow Transplant.* 2002;**8**(7):387-394.
- Malcherek, G., Jin, N., Huckelhoven, A.G. *et al.* Mesenchymal stromal cells inhibit proliferation of virus-specific CD8(+) T cells. *Leukemia* 2014;**28**(12):2388-2394.
- Mallhi, K., Lum, L.G., Schultz, K.R. *et al.* Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies. *Pediatr. Clin. North Am.* 2015;**62**(1):257-273.
- Mansour, A., Abou-Ezzi, G., Sitnicka, E. *et al.* Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. *J. Exp. Med.* 2012;**209**(3):537-549.
- Marcondes, A.M., Mhyre, A.J., Stirewalt, D.L. *et al.* Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. *Proc. Natl. Acad. Sci. U. S. A.* 2008;**105**(8):2865-2870.
- Martin, P. J., Uberti, J. P., and Soiffer, R. J. Prochymal improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GVHD. *Bone Marrow Transplant.* **45**, S17. 3-1-2010.
- Martini, G. and Zulian, F. Juvenile idiopathic arthritis: current and future treatment options. *Expert. Opin. Pharmacother.* 2006;**7**(4):387-399.
- Mastrokolias, A., den Dunnen, J.T., van Ommen, G.B. *et al.* Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA. *BMC. Genomics* 2012;**13**:28.
- Medyouf, H., Mossner, M., Jann, J.C. *et al.* Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. *Cell Stem Cell* 2014;**14**(6):824-837.
- Meisel, R., Zibert, A., Laryea, M. *et al.* Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood* 2004;**103**(12):4619-4621.
- Melief, S.M., Geutskens, S.B., Fibbe, W.E. *et al.* Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. *Haematologica* 2013;**98**(6):888-895.
- Mendez-Ferrer, S., Lucas, D., Battista, M. *et al.* Haematopoietic stem cell release is regulated by circadian oscillations. *Nature* 2008;**452**(7186):442-447.
- Mendez-Ferrer, S., Michurina, T.V., Ferraro, F. *et al.* Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 2010;**466**(7308):829-834.
- Menendez, P., Catalina, P., Rodriguez, R. *et al.* Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor

- and express the MLL-AF4 fusion gene. *J. Exp. Med.* 2009;**206**(13):3131-3141.
- Messina,C., Locatelli,F., Lanino,E. *et al.* Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. *Br. J. Haematol.* 2003;**122**(1):118-127.
- Miklos,D.B., Kim,H.T., Zorn,E. *et al.* Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. *Blood* 2004;**103**(1):353-359.
- Milano,F. and Boelens,J.J. Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source? *Cytotherapy.* 2015.
- Minami,M., Inoue,M., Wei,S. *et al.* STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. *Proc. Natl. Acad. Sci. U. S. A* 1996;**93**(9):3963-3966.
- Mohseny,A.B., Szuhai,K., Romeo,S. *et al.* Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. *J. Pathol.* 2009;**219**(3):294-305.
- Morikawa,S., Mabuchi,Y., Kubota,Y. *et al.* Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. *J. Exp. Med.* 2009;**206**(11):2483-2496.
- Morrison,S.J. and Scadden,D.T. The bone marrow niche for haematopoietic stem cells. *Nature* 2014;**505**(7483):327-334.
- Mougiakakos,D., Jitschin,R., Johansson,C.C. *et al.* The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. *Blood* 2011;**117**(18):4826-4835.
- Muller,I., Kordowich,S., Holzwarth,C. *et al.* Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. *Blood Cells Mol. Dis.* 2008;**40**(1):25-32.
- N**
- Narendran,A., Hawkins,L.M., Ganjavi,H. *et al.* Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. *Pediatr. Hematol. Oncol.* 2004;**21**(3):209-221.
- Nauta,A.J., Westerhuis,G., Kruisselbrink,A.B. *et al.* Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. *Blood* 2006;**108**(6):2114-2120.
- Naveiras,O., Nardi,V., Wenzel,P.L. *et al.* Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature* 2009;**460**(7252):259-263.
- Nemeth,K., Leelahavanichkul,A., Yuen,P.S. *et al.* Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat. Med.* 2009;**15**(1):42-49.
- NHL Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin. Pharmacol. Ther.* 2001;**69**(3):89-95.
- Niemeyer,C.M., Arico,M., Basso,G. *et al.* Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). *Blood* 1997;**89**(10):3534-3543.
- Niemeyer,C.M. and Kratz,C.P. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. *Br. J. Haematol.* 2008;**140**(6):610-624.
- Nigrovic,P.A., Mannion,M., Prince,F.H. *et al.* Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. *Arthritis Rheum.* 2011;**63**(2):545-555.
- Noort,W.A., Kruisselbrink,A.B., in't Anker,P.S. *et al.* Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived

CD34(+) cells in NOD/SCID mice. *Exp. Hematol.* 2002;**30**(8):870-878.

O

Oliveira,F.M., Lucena-Araujo,A.R., Favarin,M.C. *et al.* Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. *Exp. Hematol.* 2013;**41**(2):198-208.

Owen,M. Marrow stromal stem cells. *J. Cell Sci. Suppl* 1988;**10**:63-76.

Ozdemir,E., St John,L.S., Gillespie,G. *et al.* Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. *Blood* 2002;**100**(10):3690-3697.

P

Paczesny,S. Discovery and validation of graft-versus-host disease biomarkers. *Blood* 2013;**121**(4):585-594.

Paczesny,S., Braun,T.M., Levine,J.E. *et al.* Elafin is a biomarker of graft-versus-host disease of the skin. *Sci. Transl. Med.* 2010;**2**(13):13ra2.

Paczesny,S., Krijanovski,O.I., Braun,T.M. *et al.* A biomarker panel for acute graft-versus-host disease. *Blood* 2009;**113**(2):273-278.

Parekkadan,B., Tilles,A.W., and Yarmush,M.L. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. *Stem Cells* 2008;**26**(7):1913-1919.

Passweg,J.R., Rabusin,M., Musso,M. *et al.* Haematopoietic stem cell transplantation for refractory autoimmune cytopenia. *Br. J. Haematol.* 2004;**125**(6):749-755.

Perez-Simon,J.A., Lopez-Villar,O., Andreu,E.J. *et al.* Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results

of a phase I/II clinical trial. *Haematologica* 2011;**96**(7):1072-1076.

Perfetti,P., Carlier,P., Strada,P. *et al.* Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. *Bone Marrow Transplant.* 2008;**42**(9):609-617.

Petersdorf,E.W. The major histocompatibility complex: a model for understanding graft-versus-host disease. *Blood* 2013;**122**(11):1863-1872.

Petty,R.E., Southwood,T.R., Manners,P. *et al.* International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J. Rheumatol.* 2004;**31**(2):390-392.

Polak,R., de,R.B., Pieters,R. *et al.* B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. *Blood* 2015.

Prasad,V.K., Lucas,K.G., Kleiner,G.I. *et al.* Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. *Biol. Blood Marrow Transplant.* 2011;**17**(4):534-541.

Prince,F.H., de Bekker-Grob,E.W., Twilt,M. *et al.* An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. *Rheumatology. (Oxford)* 2011;**50**(6):1131-1136.

Prins,H.J., Rozemuller,H., Vonk-Griffioen,S. *et al.* Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum. *Tissue Eng Part A* 2009;**15**(12):3741-3751.

Prockop,D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 1997;**276**(5309):71-74.

Q

- Qian,J., Xie,J., Hong,S. *et al.* Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. *Blood* 2007;**110**(5):1587-1594.
- Qian,J., Yao,D.M., Lin,J. *et al.* Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. *Int. J. Lab Hematol.* 2010;**32**(1 Pt 2):74-81.
- Qian,J., Zheng,Y., Zheng,C. *et al.* Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. *Blood* 2012;**119**(1):161-169.
- Quartier,P., Allantaz,F., Cimaz,R. *et al.* Extended report: a multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). *Ann. Rheum. Dis.* 2011;**70**(5):747-754.

R

- R Development Core Team. R: A language and environment for statistical computing. 2012. Vienna, Austria.
- Raaijmakers,M.H. Myelodysplastic syndromes: revisiting the role of the bone marrow micro-environment in disease pathogenesis. *Int. J. Hematol.* 2012;**95**(1):17-25.
- Raaijmakers,M.H., Mukherjee,S., Guo,S. *et al.* Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature* 2010;**464**(7290):852-857.
- Rafei,M., Hsieh,J., Fortier,S. *et al.* Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. *Blood* 2008;**112**(13):4991-4998.
- Raffaghello,L., Bianchi,G., Bertolotto,M. *et al.* Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. *Stem Cells* 2008;**26**(1):151-162.
- Rao,K., Rao,A., Karlsson,H. *et al.* Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. *J. Pediatr. Hematol. Oncol.* 2009;**31**(6):456-461.
- Rasmusson,I., Ringden,O., Sundberg,B. *et al.* Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. *Exp. Cell Res.* 2005;**305**(1):33-41.
- Raval,A., Tanner,S.M., Byrd,J.C. *et al.* Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. *Cell* 2007;**129**(5):879-890.
- Ren,G., Zhang,L., Zhao,X. *et al.* Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* 2008;**2**(2):141-150.
- Resnick,I., Stepensky,P., Elkin,G. *et al.* MSC for the improvement of hematopoietic engraftment. *Bone Marrow Transplant.* 2010;**45**(3):605-606.
- Ringden,O., Uzunel,M., Rasmusson,I. *et al.* Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation* 2006;**81**(10):1390-1397.
- Ringden,O., Uzunel,M., Sundberg,B. *et al.* Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. *Leukemia* 2007;**21**(11):2271-2276.
- Robinson,M.D., McCarthy,D.J., and Smyth,G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;**26**(1):139-140.
- Rodriguez-Otero,P., Porcher,R., Peffault de,L.R. *et al.* Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. *Blood* 2012;**119**(24):5909-5917.
- Roela,R.A., Carraro,D.M., Brentani,H.P. *et al.* Gene stage-specific expression in the microenviron-

ment of pediatric myelodysplastic syndromes. *Leuk. Res.* 2007;**31**(5):579-589.

S

- Sacchetti,B., Funari,A., Michienzi,S. *et al.* Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell* 2007;**131**(2):324-336.
- Samuelsson,H., Ringden,O., Lonnies,H. *et al.* Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. *Cytotherapy.* 2009;**11**(2):129-136.
- Santamaria,C., Muntion,S., Roson,B. *et al.* Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. *Haematologica* 2012;**97**(8):1218-1224.
- Sarantopoulos,S., Stevenson,K.E., Kim,H.T. *et al.* Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. *Blood* 2009;**113**(16):3865-3874.
- Sasaki,H., Manabe,A., Kojima,S. *et al.* Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. *Leukemia* 2001;**15**(11):1713-1720.
- Schallmoser,K., Bartmann,C., Rohde,E. *et al.* Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. *Transfusion* 2007;**47**(8):1436-1446.
- Schena,F., Gambini,C., Gregorio,A. *et al.* Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. *Arthritis Rheum.* 2010;**62**(9):2776-2786.
- Schepers,K., Campbell,T.B., and Passegue,E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. *Cell Stem Cell* 2015;**16**(3):254-267.
- Schepers,K., Hsiao,E.C., Garg,T. *et al.* Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. *Blood* 2012;**120**(17):3425-3435.
- Schepers,K., Pietras,E.M., Reynaud,D. *et al.* Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche. *Cell Stem Cell* 2013;**13**(3):285-299.
- Schofield,R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells* 1978;**4**(1-2):7-25.
- Schreck,C., Bock,F., Grziwotk,S. *et al.* Regulation of hematopoiesis by activators and inhibitors of Wnt signaling from the niche. *Ann. N. Y. Acad. Sci.* 2014;**1310**:32-43.
- Schultz,K.R., Paquet,J., Bader,S. *et al.* Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. *Bone Marrow Transplant.* 1995;**16**(2):289-295.
- Scuderi,N., Ceccarelli,S., Onesti,M.G. *et al.* Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. *Cell Transplant.* 2013;**22**(5):779-795.
- Selmani,Z., Naji,A., Zidi,I. *et al.* Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. *Stem Cells* 2008;**26**(1):212-222.
- Shimomura,Y., Agalliu,D., Vonica,A. *et al.* APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex. *Nature* 2010;**464**(7291):1043-1047.
- Sica,A., Schioppa,T., Mantovani,A. *et al.* Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. *Eur. J. Cancer* 2006;**42**(6):717-727.
- Smyth,G. (2005). Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor, V.C.S.D.R.I.W.H.R.Gentleman, ed. (New York, NY, USA: Springer), pp. 397-420.
- Soenen-Cornu,V., Tourino,C., Bonnet,M.L. *et al.* Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid

- of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. *Oncogene* 2005;**24**(15):2441-2448.
- Song,L., Webb,N.E., Song,Y. *et al.* Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. *Stem Cells* 2006;**24**(7):1707-1718.
- Song,L.X., Guo,J., He,Q. *et al.* Bone marrow mesenchymal stem cells in myelodysplastic syndromes: cytogenetic characterization. *Acta Haematol.* 2012;**128**(3):170-177.
- Sotiropoulou,P.A., Perez,S.A., Gritzapis,A.D. *et al.* Interactions between human mesenchymal stem cells and natural killer cells. *Stem Cells* 2006;**24**(1):74-85.
- Spaggiari,G.M., Capobianco,A., Abdelrazik,H. *et al.* Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. *Blood* 2008;**111**(3):1327-1333.
- Spaggiari,G.M., Capobianco,A., Becchetti,S. *et al.* Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* 2006;**107**(4):1484-1490.
- Srinivasan,M., Flynn,R., Price,A. *et al.* Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. *Blood* 2012;**119**(6):1570-1580.
- Strahm,B., Nollke,P., Zecca,M. *et al.* Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. *Leukemia* 2011;**25**(3):455-462.
- Sugiyama,T., Kohara,H., Noda,M. *et al.* Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity.* 2006a;**25**(6):977-988.
- Sugiyama,T., Kohara,H., Noda,M. *et al.* Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity.* 2006b;**25**(6):977-988.
- Sun,L., Akiyama,K., Zhang,H. *et al.* Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. *Stem Cells* 2009;**27**(6):1421-1432.
- Sun,L., Wang,D., Liang,J. *et al.* Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. *Arthritis Rheum.* 2010;**62**(8):2467-2475.
- Sundin,M., Orvell,C., Rasmusson,I. *et al.* Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. *Bone Marrow Transplant.* 2006;**37**(11):1051-1059.
- ## T
- Tanner,J. and Tosato,G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. *J. Clin. Invest* 1991;**88**(1):239-247.
- Tennant,G.B., Walsh,V., Truran,L.N. *et al.* Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. *Br. J. Haematol.* 2000;**111**(3):853-862.
- Thanopoulou,E., Cashman,J., Kakagianne,T. *et al.* Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. *Blood* 2004;**103**(11):4285-4293.
- Traggiai,E., Volpi,S., Schena,F. *et al.* Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. *Stem Cells* 2008a;**26**(2):562-569.
- Traggiai,E., Volpi,S., Schena,F. *et al.* Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. *Stem Cells* 2008b;**26**(2):562-569.

U

Uccelli,A., Moretta,L., and Pistoia,V. Mesenchymal stem cells in health and disease. *Nat. Rev. Immunol.* 2008;**8**(9):726-736.

V

- van den Berk,L.C., van,d., V, Willemse,M.E. *et al.* Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. *Br. J. Haematol.* 2014;**166**(2):240-249.
- van Els,C.A., Bakker,A., Zwinderman,A.H. *et al.* Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. *Transplantation* 1990;**50**(1):67-71.
- van Tol,M.J., Claas,E.C., Heemskerk,B. *et al.* Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. *Bone Marrow Transplant.* 2005a;**35 Suppl 1**:S73-S76.
- van Tol,M.J., Kroes,A.C., Schinkel,J. *et al.* Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. *Bone Marrow Transplant.* 2005b;**36**(1):39-50.
- Varga,G., Kiss,J., Varkonyi,J. *et al.* Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. *Pathol. Oncol. Res.* 2007;**13**(4):311-319.
- Vastert,S.J., Kuis,W., and Grom,A.A. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. *Best. Pract. Res. Clin. Rheumatol.* 2009;**23**(5):655-664.
- Veltrop-Duits,L.A., Heemskerk,B., Sombroek,C.C. *et al.* Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. *Eur. J. Immunol.* 2006;**36**(9):2410-2423.
- von Bahr,L., Sundberg,B., Lonnie,L. *et al.* Long-term complications, immunologic effects, and

role of passage for outcome in mesenchymal stromal cell therapy. *Biol. Blood Marrow Transplant.* 2012;**18**(4):557-564.

- von Bonin,M., Stolzel,F., Goedecke,A. *et al.* Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. *Bone Marrow Transplant.* 2009;**43**(3):245-251.
- Vossen,J.M., Guiot,H.F., Lankester,A.C. *et al.* Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation. *PLoS. One.* 2014;**9**(9):e105706.
- Vossen,J.M., Heidt,P.J., van den Berg,H. *et al.* Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. *Eur. J. Clin. Microbiol. Infect. Dis.* 1990;**9**(1):14-23.

W

- Walkley,C.R., Olsen,G.H., Dworkin,S. *et al.* A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. *Cell* 2007;**129**(6):1097-1110.
- Walls,T., Shankar,A.G., and Shingadia,D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. *Lancet Infect. Dis.* 2003;**3**(2):79-86.
- Wang,D., Zhang,H., Liang,J. *et al.* Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. *Cell Transplant.* 2013a;**22**(12):2267-2277.
- Wang,X., Hisha,H., Mizokami,T. *et al.* Mouse mesenchymal stem cells can support human hematopoiesis both in vitro and in vivo: the crucial role of neural cell adhesion molecule. *Haematologica* 2010;**95**(6):884-891.
- Wang,Z., Tang,X., Xu,W. *et al.* The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or

- high-risk myelodysplastic syndromes. *PLoS. One.* 2013b;**8**(3):e57470.
- Washington,K. and Jagasia,M. Pathology of graft-versus-host disease in the gastrointestinal tract. *Hum. Pathol.* 2009;**40**(7):909-917.
- Waterman,R.S., Tomchuck,S.L., Henkle,S.L. *et al.* A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. *PLoS. One.* 2010;**5**(4):e10088.
- Weng,J.Y., DU,X., Geng,S.X. *et al.* Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. *Bone Marrow Transplant.* 2010;**45**(12):1732-1740.
- Wilhelm,K., Ganesan,J., Muller,T. *et al.* Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. *Nat. Med.* 2010;**16**(12):1434-1438.
- Winkler,I.G., Sims,N.A., Pettit,A.R. *et al.* Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. *Blood* 2010;**116**(23):4815-4828.
- Woo,P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. *Ann. Rheum. Dis.* 2008;**67**(3):281-282.
- Woods,W.G., Barnard,D.R., Alonzo,T.A. *et al.* Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. *J. Clin. Oncol.* 2002;**20**(2):434-440.
- World Medical Association. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. *JAMA* 1997;**277**(11):925-926.
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;**310**(20):2191-2194.
- Wu,X., Liu,W., Tian,Y. *et al.* Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes. *Acta Haematol.* 2011;**125**(4):179-185.

X

- Xu,Y., Sun,J., Sheard,M.A. *et al.* Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFbeta1. *Cancer Immunol. Immunother.* 2013;**62**(10):1637-1648.

Y

- Yokota,S., Imagawa,T., Mori,M. *et al.* Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet* 2008;**371**(9617):998-1006.
- Youd,M., Blickarz,C., Woodworth,L. *et al.* Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. *Clin. Exp. Immunol.* 2010;**161**(1):176-186.

Z

- Zandvliet,M.L., van,L.E., Jedema,I. *et al.* Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. *J. Immunother.* 2011;**34**(3):307-319.
- Zangi,L., Margalit,R., Reich-Zeliger,S. *et al.* Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. *Stem Cells* 2009;**27**(11):2865-2874.
- Zappia,E., Casazza,S., Pedemonte,E. *et al.* Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood* 2005;**106**(5):1755-1761.
- Zhang,B., Ho,Y.W., Huang,Q. *et al.* Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. *Cancer Cell* 2012a;**21**(4):577-592.

- Zhang,B., Ho,Y.W., Huang,Q. *et al.* Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. *Cancer Cell* 2012b;**21**(4):577-592.
- Zhang,C., Todorov,I., Zhang,Z. *et al.* Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. *Blood* 2006;**107**(7):2993-3001.
- Zhang,H., Nguyen-Jackson,H., Panopoulos,A.D. *et al.* STAT3 controls myeloid progenitor growth during emergency granulopoiesis. *Blood* 2010;**116**(14):2462-2471.
- Zhang,J., Li,Y., Chen,J. *et al.* Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. *Exp. Neurol.* 2005;**195**(1):16-26.
- Zhang,J., Niu,C., Ye,L. *et al.* Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 2003;**425**(6960):836-841.
- Zhao,Y., Wu,D., Fei,C. *et al.* Downregulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome. *Haematologica* 2014.
- Zhao,Z., Wang,Z., Li,Q. *et al.* The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes. *PLoS. One.* 2012a;**7**(9):e45675.
- Zhao,Z.G., Xu,W., Yu,H.P. *et al.* Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. *Cancer Lett.* 2012b;**317**(2):136-143.
- Zhou,H., Guo,M., Bian,C. *et al.* Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. *Biol. Blood Marrow Transplant.* 2010;**16**(3):403-412.
- Zou,J., Hong,Y., Tong,Y. *et al.* Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. *Stem Cells Int.* 2015;**2015**:957502.

